Please ensure Javascript is enabled for purposes of website accessibility

Why Cara Therapeutics Shares Are Rallying Again Today

By Todd Campbell – Jun 26, 2017 at 4:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor optimism remains high, following news that Cara's lead drug candidate received FDA breakthrough-therapy status for use in patients with kidney disease.

What happened

On Friday, shares in Cara Therapeutics (CARA -7.67%) shot higher after management reported that the U.S. Food and Drug Administration had awarded "breakthrough therapy" designation to the IV formulation of its anti-pain and anti-itch medicine CR845, for uremic pruritis, or chronic itch, in patients with kidney disease. Today, shares are up an additional 9.5% at 3:30 p.m. EDT.

So what

Earlier this year, Cara Therapeutics reported phase 2/3 data from part A of its study showing that CR845 might provide welcome relief of uremic pruritis.

Scientists work together developing medicine in a lab.


Specifically, CR845 patients had a 68% reduction in pain versus a placebo, based on a 0-to-10 rating scale after eight weeks of treatment. CR845 also delivered a 100% greater reduction versus a placebo on the Skindex-10 scale, which measures quality of life.

The findings were good enough for the FDA to award the drug breakthrough status because current treatments, including antihistamines and corticosteroids, often fall short for many patients. Since uremic pruritus can be a big cause of diminishing quality of life in these patients, new treatment options are necessary.

Now what

There are 468,000 Americans with kidney failure who are on dialysis. About 60% of them suffer from uremic pruritus, and between 30% and 40% of them report it to be moderate to severe.

While winning breakthrough designation doesn't guarantee future FDA approval, it does provide management with ongoing FDA assistance that can help it avoid pitfalls and improve the likelihood of crossing the finish line. Of course, any filing for FDA approval will depend on the phase 3 part of this study confirming the strong efficacy and safety observed in part A.

Investors should also know that CR845 is being evaluated in other indications, including postoperative pain and osteoarthritis. Unlike opioids, CR845 doesn't cross the blood-brain barrier, and thus it may have fewer side effects and produce less euphoria than opioids. Because there's significant desire to reduce the use of opioids, CR845 has the potential to reshape pain treatment.

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.